Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant
Verismo Therapeutics, a clinical-stage CAR T company, has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant will support the optimization of Verismo's KIR-CAR platform development and manufacturing using the G-Rex technology. The grant is part of ScaleReady's $20 million program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing.
As part of the grant, Verismo will optimize their G-Rex-based KIR-CAR T process and implement it as a platform manufacturing process. The company will also evaluate critical reagents from Bio-Techne, including GMP cytokines and the new ProPakTM GMP cytokines line, estimated to be commercially available by the end of 2024.
Verismo Therapeutics, un'azienda clinica nel settore delle CAR T, ha ricevuto un grant G-Rex di 150.000 dollari da ScaleReady™. Questo grant sosterrà l'ottimizzazione dello sviluppo e della produzione della piattaforma KIR-CAR di Verismo utilizzando la tecnologia G-Rex. Il grant è parte del programma da 20 milioni di dollari di ScaleReady, volto a promuovere lo sviluppo e la produzione di Terapie Cellulari e Geniche (CGT).
Come parte del grant, Verismo ottimizzerà il proprio processo KIR-CAR T basato su G-Rex e lo implementerà come processo di produzione della piattaforma. L'azienda valuterà anche i reagenti critici forniti da Bio-Techne, inclusi i citochine GMP e la nuova linea di citochine GMP ProPakTM, prevista in commercio entro la fine del 2024.
Verismo Therapeutics, una empresa en etapa clínica de CAR T, ha sido galardonada con una subvención G-Rex de $150,000 por ScaleReady™. Esta subvención respaldará la optimización del desarrollo y la fabricación de la plataforma KIR-CAR de Verismo utilizando la tecnología G-Rex. La subvención forma parte del programa de $20 millones de ScaleReady, que tiene como objetivo avanzar en el desarrollo y la fabricación de Terapias Celulares y Genéticas (CGT).
Como parte de la subvención, Verismo optimizará su proceso KIR-CAR T basado en G-Rex e implementará este proceso como el proceso de fabricación de la plataforma. La empresa también evaluará reactivos críticos de Bio-Techne, incluidos citoquinas GMP y la nueva línea de citoquinas GMP ProPakTM, que se espera esté disponible comercialmente para finales de 2024.
Verismo Therapeutics는 CAR T 임상 단계 회사로서 ScaleReady™로부터 150,000달러의 G-Rex 보조금을 수여받았습니다. 이 보조금은 G-Rex 기술을 사용하여 Verismo의 KIR-CAR 플랫폼 개발 및 제조 최적화를 지원할 것입니다. 이 보조금은 세포 및 유전자 치료(CGT) 개발 및 제조를 촉진하기 위한 ScaleReady의 2천만 달러 프로그램의 일환입니다.
보조금의 일환으로 Verismo는 G-Rex 기반 KIR-CAR T 프로세스를 최적화하고 이를 플랫폼 제조 프로세스로 구현할 것입니다. 또한 회사는 Bio-Techne의 주요 시약을 평가할 예정이며, 여기에는 GMP 사이토카인과 2024년 말 상용화가 예상되는 새로운 ProPakTM GMP 사이토카인 라인이 포함됩니다.
Verismo Therapeutics, une entreprise de CAR T en phase clinique, a reçu un subvention G-Rex de 150 000 $ de ScaleReady™. Cette subvention soutiendra l'optimisation du développement et de la fabrication de la plateforme KIR-CAR de Verismo utilisant la technologie G-Rex. La subvention fait partie du programme de 20 millions de dollars de ScaleReady, visant à faire progresser le développement et la fabrication des thérapies cellulaires et géniques (CGT).
Dans le cadre de la subvention, Verismo optimisera son processus KIR-CAR T basé sur G-Rex et le mettra en œuvre comme processus de fabrication de plateforme. L'entreprise évaluera également des réactifs critiques de Bio-Techne, y compris des cytokines GMP et la nouvelle ligne de cytokines GMP ProPakTM, qui devraient être commercialement disponibles d'ici la fin de 2024.
Verismo Therapeutics, ein klinisches CAR T-Unternehmen, wurde mit einem 150.000 $ G-Rex-Stipendium von ScaleReady™ ausgezeichnet. Dieses Stipendium unterstützt die Optimierung der Entwicklung und Herstellung der KIR-CAR-Plattform von Verismo unter Verwendung der G-Rex-Technologie. Das Stipendium ist Teil von ScaleReadys 20 Millionen Dollar-Programm, das darauf abzielt, die Entwicklung und Herstellung von Zell- und Gentherapien (CGT) voranzutreiben.
Im Rahmen des Stipendiums wird Verismo ihren G-Rex-basierten KIR-CAR T-Prozess optimieren und ihn als Plattform-Herstellungsprozess implementieren. Das Unternehmen wird auch kritische Reagenzien von Bio-Techne bewerten, darunter GMP-Zytokine und die neue ProPakTM GMP-Zytokine-Linie, die voraussichtlich Ende 2024 kommerziell erhältlich sein wird.
- Received $150,000 G-Rex Grant to optimize manufacturing processes
- Potential for more efficient and cost-effective delivery of treatments
- Early access to new closed system reagents (ProPakTM GMP cytokines) from Bio-Techne
- None.
The G-Rex Grant is part of ScaleReady's
"We are grateful to have been chosen for the G-Rex Grant at Verismo Therapeutics," stated Raymond Luke, Director of Manufacturing Science and Technology at Verismo Therapeutics. "This funding will help us further optimize our cell therapy manufacturing processes by transitioning our active and future pipeline to G-Rex®, ensuring we can deliver life-saving treatments to patients more efficiently and cost-effectively. We are excited to work with ScaleReady to drive forward innovative solutions in cell therapy production."
"We are excited to support Verismo Therapeutics through the G-Rex Grant program. Their commitment to advancing cell and gene therapy aligns perfectly with our mission to provide hope to cancer patients one G-Rex at a time. We look forward to seeing the impactful advancements Verismo Therapeutics will achieve with this grant." said John Wilson, CEO of Wilson Wolf Manufacturing and co-inventor of G-Rex.
As part of the G-Rex® Grant, Verismo will complete optimization of their G-Rex-based KIR-CAR T process and plans to implement this as a platform manufacturing process. Additionally, Verismo will evaluate a suite of critical reagents from Bio-Techne (R&D Systems) including GMP cytokines. Specifically, Verismo will get early access to a line of new, closed system reagents from Bio-Techne, called ProPakTM GMP cytokines, that are tailor-made for use with G-Rex. The ProPakTM line of GMP reagents are estimated to be commercially available by the end of 2024.
Verismo Therapeutics is committed to pioneering new therapies and technologies that improve patient outcomes. The G-Rex Grant will play a pivotal role in advancing the company's research and development efforts, ultimately contributing to the broader goal of making innovative treatments accessible to those in need.
About the KIR-CAR Platform
The KIR-CAR platform is a multi-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging tumor microenvironments. Using NK cell derived KIR and DAP12 split signaling provides a novel combined activation and co-stimulation separate from the usual T cell stimulation pathways. It also enables sustained chimeric receptor expression and improves KIR-CAR T cell long term function. This results in prolonged T cell functional persistence and leads to regression of solid tumors in preclinical models that are resistant to traditional CAR T cell therapies.
About Verismo Therapeutics
Verismo Therapeutics is a pioneer in multi-chain KIR-CAR technology, with its first assets SynKIR™-110 and SynKIR™-310 currently in Phase 1 clinical trials. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell derived receptor and DAP12 pairing, designed to improve persistence and efficacy against aggressive tumors. The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B cell associated disorders and malignancies. For more information, visit: www.verismotherapeutics.com
About ScaleReady™
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing Corporation
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/verismo-therapeutics-awarded-a-scaleready-g-rex-grant-302249877.html
SOURCE Verismo Therapeutics
FAQ
What is the value of the G-Rex Grant awarded to Verismo Therapeutics?
How will Verismo Therapeutics use the G-Rex Grant?
What new reagents will Verismo Therapeutics evaluate as part of the G-Rex Grant?
When are the ProPakTM GMP cytokines expected to be commercially available?
